Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary Innovations
Zomedica Corp. (OTCQB:ZOMDF) has announced the launch of a new monthly webinar series called "Fourth Friday at Four" starting May 23rd, 2025. The series aims to showcase the company's innovative veterinary health products and technologies to investors, veterinarians, and industry partners.
The webinars will highlight Zomedica's product portfolio including the PulseVet® Shock Wave system for musculoskeletal healing, Assisi Loop® and Calmer Canine for pain management and anxiety, TRUFORMA® diagnostic platform, TRUVIEW® Digital Cytology System, VETGuardian® monitoring system, and VETIGEL® hemostatic gel. CEO Larry Heaton emphasized that the series will focus on building a community of professionals while providing insights into the company's technologies and growth strategy.
Zomedica Corp. (OTCQB:ZOMDF) ha annunciato il lancio di una nuova serie di webinar mensili chiamata "Fourth Friday at Four", a partire dal 23 maggio 2025. La serie ha l'obiettivo di presentare agli investitori, veterinari e partner del settore i prodotti e le tecnologie innovative dell'azienda nel campo della salute veterinaria.
I webinar metteranno in evidenza il portafoglio prodotti di Zomedica, tra cui il PulseVet® Shock Wave system per la guarigione muscoloscheletrica, Assisi Loop® e Calmer Canine per la gestione del dolore e dell'ansia, la piattaforma diagnostica TRUFORMA®, il sistema di citologia digitale TRUVIEW®, il sistema di monitoraggio VETGuardian® e il gel emostatico VETIGEL®. Il CEO Larry Heaton ha sottolineato che la serie sarà focalizzata sulla creazione di una comunità di professionisti, offrendo al contempo approfondimenti sulle tecnologie dell'azienda e sulla sua strategia di crescita.
Zomedica Corp. (OTCQB:ZOMDF) ha anunciado el lanzamiento de una nueva serie de seminarios web mensuales llamada "Fourth Friday at Four", que comenzará el 23 de mayo de 2025. La serie tiene como objetivo mostrar los productos y tecnologías innovadoras de salud veterinaria de la compañía a inversores, veterinarios y socios del sector.
Los seminarios web destacarán el portafolio de productos de Zomedica, incluyendo el Sistema de Ondas de Choque PulseVet® para la curación musculoesquelética, Assisi Loop® y Calmer Canine para el manejo del dolor y la ansiedad, la plataforma diagnóstica TRUFORMA®, el sistema de citología digital TRUVIEW®, el sistema de monitoreo VETGuardian® y el gel hemostático VETIGEL®. El CEO Larry Heaton enfatizó que la serie se centrará en construir una comunidad de profesionales mientras proporciona información sobre las tecnologías de la compañía y su estrategia de crecimiento.
Zomedica Corp. (OTCQB:ZOMDF)는 2025년 5월 23일부터 시작하는 새로운 월간 웨비나 시리즈 "Fourth Friday at Four"를 발표했습니다. 이 시리즈는 투자자, 수의사 및 업계 파트너들에게 회사의 혁신적인 수의학 건강 제품과 기술을 소개하는 것을 목표로 합니다.
웨비나에서는 근골격계 치유를 위한 PulseVet® Shock Wave 시스템, 통증 관리 및 불안 완화를 위한 Assisi Loop® 및 Calmer Canine, 진단 플랫폼 TRUFORMA®, 디지털 세포학 시스템 TRUVIEW®, 모니터링 시스템 VETGuardian®, 그리고 지혈 젤 VETIGEL® 등 Zomedica의 제품 포트폴리오를 강조할 예정입니다. CEO Larry Heaton은 이 시리즈가 전문가 커뮤니티를 구축하는 데 중점을 두면서 회사의 기술과 성장 전략에 대한 통찰을 제공할 것이라고 강조했습니다.
Zomedica Corp. (OTCQB:ZOMDF) a annoncé le lancement d'une nouvelle série de webinaires mensuels intitulée "Fourth Friday at Four", à partir du 23 mai 2025. Cette série vise à présenter les produits et technologies innovants de santé vétérinaire de l'entreprise aux investisseurs, vétérinaires et partenaires de l'industrie.
Les webinaires mettront en lumière le portefeuille de produits de Zomedica, incluant le système d'ondes de choc PulseVet® pour la guérison musculo-squelettique, Assisi Loop® et Calmer Canine pour la gestion de la douleur et de l'anxiété, la plateforme diagnostique TRUFORMA®, le système de cytologie numérique TRUVIEW®, le système de surveillance VETGuardian® et le gel hémostatique VETIGEL®. Le PDG Larry Heaton a souligné que cette série se concentrera sur la création d'une communauté de professionnels tout en offrant des perspectives sur les technologies de l'entreprise et sa stratégie de croissance.
Zomedica Corp. (OTCQB:ZOMDF) hat die Einführung einer neuen monatlichen Webinar-Reihe namens "Fourth Friday at Four" ab dem 23. Mai 2025 angekündigt. Die Reihe soll Investoren, Tierärzten und Branchenpartnern die innovativen veterinärmedizinischen Produkte und Technologien des Unternehmens vorstellen.
Die Webinare werden Zomedicas Produktportfolio hervorheben, darunter das PulseVet® Shock Wave System zur muskulären und skelettalen Heilung, Assisi Loop® und Calmer Canine zur Schmerz- und Angstbewältigung, die diagnostische Plattform TRUFORMA®, das digitale Zytologiesystem TRUVIEW®, das Überwachungssystem VETGuardian® sowie das hämostatische Gel VETIGEL®. CEO Larry Heaton betonte, dass die Reihe darauf abzielt, eine Gemeinschaft von Fachleuten aufzubauen und gleichzeitig Einblicke in die Technologien und Wachstumsstrategie des Unternehmens zu bieten.
- None.
- None.
Engaging Sessions to Highlight Game-Changing Technologies, Expert Insights, and Growth Opportunities in Animal Health Featuring Zomedica Products
ANN ARBOR, MI / ACCESS Newswire / May 19, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the launch of a new monthly webinar series designed to highlight its innovative product portfolio, introduce key personnel, showcase manufacturing capabilities, and educate investors and strategic partners on the company's long-term growth strategy.
This exclusive webinar series scheduled for the fourth Friday of every month beginning May 23rd, offers a front-row seat to Zomedica's game-changing technologies and strategic vision, providing veterinarians, investors, and industry leaders with an unparalleled opportunity to stay ahead of the curve in animal healthcare. Attendees will gain first-hand insights into cutting-edge advancements that are shaping the future of veterinary medicine while discovering how Zomedica is driving innovation, expanding its market presence, and delivering solutions that improve patient outcomes.
Each engaging session will dive deep into Zomedica's groundbreaking technologies, including the:
PulseVet® Shock Wave system - A revolutionary, non-invasive therapy accelerating healing in musculoskeletal conditions, setting new standards in veterinary therapeutics.
Assisi Loop® and Calmer Canine products - Advanced tPEMF™ (Targeted Pulsed Electromagnetic Field) therapy devices that provide drug-free, highly effective pain and inflammation management, as well as the Calmer Canine therapy for behavioral separation anxiety.
TRUFORMA® Diagnostic Platform - A next-generation in-clinic system offering unique, precise, rapid diagnostic testing to support complex veterinary cases with unparalleled accuracy at the point of care.
TRUVIEW® Digital Cytology System: Best-in-class imaging and the only fully automated slide prep solution-ensuring consistent quality, telepathology-backed confidence, and a streamlined workflow for faster, more accurate diagnoses in veterinary medicine.
VETGuardian® No-Touch Monitoring System - A state-of-the-art, contact-free monitoring solution ensuring continuous remote tracking of vital signs for enhanced patient care.
VETIGEL® - An innovative, plant-based hemostatic gel designed for rapid and effective bleeding control, revolutionizing wound management in veterinary medicine.
"Zomedica's monthly webinar series isn't just about showcasing our products-it's about building a community of forward-thinking professionals and investors dedicated to advancing animal healthcare," said Larry Heaton, CEO of Zomedica. "Through these interactive sessions, we are offering an exclusive look at our industry-leading technologies, expert-driven discussions, and our commitment to driving growth and innovation in veterinary medicine."
Designed to be interactive and insightful, each webinar will feature product demonstrations, in-depth discussions with industry experts, and Q&A opportunities with Zomedica's leadership team. Investors and strategic partners will gain a deeper understanding of the company's expanding market influence, robust R&D pipeline, and vision for sustainable revenue growth and shareholder value.
Webinar Registration & Details
Don't miss this opportunity to connect with industry experts, discover groundbreaking technologies, and explore new possibilities in veterinary healthcare. The series is open to veterinary professionals, industry partners, investors, and all who are interested in improving the lives of our family pets.
To secure your spot in the upcoming sessions, click on the link below https://us02web.zoom.us/webinar/register/WN_lUpmJTicRliHUCVyz6JEbg or visit www.investors.zomedica.com.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes;; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
FAQ
What products will Zomedica (ZOM) showcase in their Fourth Friday webinar series?
When does Zomedica's (ZOM) Fourth Friday at Four webinar series begin?
Who can attend Zomedica's (ZOM) monthly webinar series?
What is the purpose of Zomedica's (ZOM) Fourth Friday webinar series?
